“Prescription drug prices are out of control,” wrote AHA President and CEO Rick Pollack and America’s Health Insurance Plans President and CEO Marilyn Tavenner in a Dec. 31 OpEd in The Hill. “The average annual cost for one specialty medication to treat a chronic condition is now more than what most families earn in a year. Big Pharma could solve the problem by committing to more rational and sustainable pricing models. Instead, for the last year, Big Pharma has chosen to point the finger at everyone else, and their decision to engage in a blame game is a tacit admission that drug prices are, in fact, too high.” To read the full column, click here.

Related News Articles

Headline
Enrollment in private health insurance plans remained concentrated among a small number of issuers in 2015 and 2016
Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The National Health Law Program and other groups yesterday filed a class action lawsuit against the Department of Health and Human Services for approving a…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…
Headline
Hospitals in states that impose Medicaid work requirements could see reduced Medicaid revenues and operating margins and increased uncompensated care costs,…
Headline
About 34 percent of uninsured U.S. adults did not take their medication as prescribed in 2017 in order to reduce their prescription drug costs, according to a…